華東醫藥(000963.SZ)：控股子公司DR10624的臨牀研究結果在2025年歐洲肝病研究學會(EASL)年會發布
格隆匯5月12日丨華東醫藥(000963.SZ)公佈，近日，華東醫藥股份有限公司控股子公司浙江道爾生物科技有限公司(簡稱“道爾生物”)自主研發的全球首創(First-in-class)的靶向成纖維細胞生長因子21受體(Fibroblastgrowth factor 21 receptor，FGF21R)、胰高血糖素受體(Glucagonreceptor，GCGR)和胰高血糖素樣肽-1 受體(Glucagon-like peptide-1receptor，GLP-1R)的長效三重激動劑 DR10624 在新西蘭治療肥胖合併高甘油三脂血癥的 Ib/IIa 期臨牀研究結果在荷蘭阿姆斯特丹舉辦的2025 年歐洲肝病研究學會年會(EASL Congress 2025)上首次發佈。研究結果 “DR10624, a First-In-Class, FGF21 Receptor (FGF21R)/Glucagon Receptor (GCGR)/GLP-1 Receptor (GLP-1R) TripleAgonist Rapidly and Significantly Reduced Liver Fat in Obese SubjectsWith Modest Hypertriglyceridemia: A 12-Week Randomized, PlaceboControlled, Double-Blind, Multi-Center Trial”入選了大會的最新突破(Late-Breaker)，展示了DR10624在肥胖合併高甘油三酯血癥受試者中取得的關鍵研究數據。
上述Ib/IIa期臨牀研究數據顯示，DR10624在臨牀每週給藥一次、連續給藥12周後，可實現具有臨牀意義的肝臟脂肪含量降低的藥效，並在血脂譜改善和胰島素敏感性提升方面展現出具有統計學意義的顯著改善的療效，使得受試者獲得綜合性的代謝獲益。在新西蘭完成的這項Ib/IIa期臨牀研究結果進一步驗證了DR10624治療重度高甘油三脂血癥(SHTG)，代謝功能障礙相關脂肪性肝病/代謝相關脂肪性肝炎(MASLD/MASH)等疾病的潛力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
